On April 23, Ge Longhui (01846.HK) announced that in the first quarter of 2024, the total number of ophthalmic surgeries performed by the Group was 7,234, an increase of 6% over the same period in 2023.
The Group's sales mix continued to change favourably throughout the first quarter of 2024 due to (i) a significant increase in the number of crystal replacement surgeries; and (ii) the opening of clinics in Hong Kong and London, which led to significant revenue growth. The Board considers this to be in line with the Group's three-year endogenous compound annual growth rate (CAGR) guidelines.